Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(04): 209-212
DOI: 10.1055/s-0041-1726140
Original Article: Hepatobiliary Cancer

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India

Prabhat G. Bhargava
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Amit Kumar
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Vijai Simha
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Minit Shah
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Shraddha Patkar
2   Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Mahesh Goel
2   Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Vikas Ostwal
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
,
Anant Ramaswamy
1   Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Parel, Mumbai, Maharashtra, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Biliary tract cancers (BTCs) are a rare group of cancers with limited data with respect to advanced unresectable cholangiocarcinoma (CCA).

Materials and Methods The study is a retrospective study of patients with advanced unresectable/metastatic CCA, who received first-line palliative chemotherapy (CT1) from January 2014 to March 2019 at the Tata Memorial Hospital, Mumbai. Baseline clinical characteristics, chemotherapeutic regimens, and toxicities were evaluated.

Results One hundred and forty patients satisfied criteria for evaluation. Median age of the entire cohort was 57 years (range: 32–80). There were 87 patients (62.1%) with intrahepatic CCA, 35 patients (25%) with perihilar CCA, and 14 patients (10%) with distal CCA. One hundred and twelve patients (80%) had metastatic disease at presentation. Commonest CT1 regimens were gemcitabine–cisplatin (GC) in 89 patients (63.5%) and gemcitabine–oxaliplatin (GO) in 34 patients (24.3%). Sixty-three patients (45%) received second-line chemotherapy. With a median follow-up of 27 months, median progression-free survival for the entire cohort was 7.56 months (95% confidence interval [CI]: 6.23–8.88), and median OS was 12.16 months (95% CI: 10.08–14.24). Common chemotherapy-related grade 3/4 side effects included vomiting in 25 patients (17.9%), diarrhea in 23 patients (16.4%), and thrombocytopenia in 22 patients (15.7%).

Conclusion The current study in advanced CCAs is the largest of its nature from India. The common regimens used as first line were GC and GO. Tolerance and overall survival appear similar to previously published data.

Keywords

biliary tract cancers - first-line palliative chemotherapy - gemcitabine–cisplatin - India - unresectable cholangiocarcinoma


Publication History

Article published online:
12 June 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Randi G, Malvezzi M, Levi F. et al. Epidemiology of biliary tract cancers: an update. Ann Oncol 2009; 20 (01) 146-159
    CrossrefPubMedGoogle Scholar
  • 2 Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol 1999; 18 (01) 24-28
    PubMedGoogle Scholar
  • 3 Engineer R, Goel M, Chopra S. et al. Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol 2016; 23 (09) 3009-3015
    CrossrefPubMedGoogle Scholar
  • 4 Ramaswamy A, Ostwal V, Pinninti R. et al. Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. J Hepatobiliary Pancreat Sci 2017; 24 (05) 262-267
    CrossrefPubMedGoogle Scholar
  • 5 Patkar S, Ostwal V, Ramaswamy A. et al. Emerging role of multimodality treatment in gall bladder cancer: outcomes following 510 consecutive resections in a tertiary referral center. J Surg Oncol 2018; 117 (03) 372-379
    CrossrefPubMedGoogle Scholar
  • 6 Valle J, Wasan H, Palmer DH. et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedGoogle Scholar
  • 7 André T, Reyes-Vidal JM, Fartoux L. et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99 (06) 862-867
    CrossrefPubMedGoogle Scholar
  • 8 Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol 2017; 90 (10/76) 2017-0061
    Google Scholar
  • 9 Kim Y-I, Park J-W, Kim BH. et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 2013; 8: 292
    CrossrefPubMedGoogle Scholar
  • 10 Babu VPK, Talwar V, Raina S. et al. Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: a study from North India Cancer Centre. Indian J Cancer 2018; 55 (03) 222-225
    CrossrefPubMedGoogle Scholar
  • 11 Okusaka T, Nakachi K, Fukutomi A. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103 (04) 469-474
    CrossrefPubMedGoogle Scholar
  • 12 Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 2018; 48 (08) 703-711
    CrossrefPubMedGoogle Scholar
  • 13 Belkouz A, de Vos-Geelen J., Mathôt R.A.A.. et al. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.. Br J Cancer 2020; 122634: 639 DOI: 10.1038/s41416-019-0698-9.
    CrossrefPubMedGoogle Scholar
  • 14 Ostwal V, Pinninti R, Ramaswamy A. et al. Treatment of advanced gall bladder cancer in the real world-can continuation chemotherapy improve outcomes?. J Gastrointest Oncol 2017; 8 (02) 368-376
    CrossrefPubMedGoogle Scholar
  • 15 Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014; 25 (12) 2328-2338
    CrossrefPubMedGoogle Scholar
  • 16 Ramaswamy A, Ostwal V, Pande N. et al. Second-line palliative chemotherapy in advanced gall bladder cancer, CAP-IRI: safe and effective option. J Gastrointest Cancer 2016; 47 (03) 305-312
    CrossrefPubMedGoogle Scholar
  • 17 Shroff RT, Javle MM, Xiao L. et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol 2019; 5 (06) 824-830
    CrossrefPubMedGoogle Scholar
  • 18 ClarIDHy and FIGHT-202 Trials Show Positive Results in the Treatment of Patients With Biliary Tract Cancer - The ASCO Post [Internet] (cited April 20, 2020). Available at: https://www.ascopost.com/issues/december-10-2019/claridhy-and-fight-202-trials-show-positive-results-in-the-treatment-of-patients-with-biliary-tract-cancer/ Accessed date - 20 April 2020